Insight 03

How to weigh your hair treatment options

Last reviewed

Published

A tablet, scalp preparation, laser device and injection make different demands on your health, time and budget. The choice starts with the condition being treated and the result you want.

A useful recommendation names the preferred option, explains its purpose and sets a point for reviewing the result. Each additional treatment needs a role in that plan.

Match the treatment to its purpose

Minoxidil supports growth. Finasteride and dutasteride reduce formation of dihydrotestosterone, or DHT, in selected plans for pattern hair loss. Anti-inflammatory and immune-directed drugs address particular scalp disorders. Trials of baricitinib, for example, demonstrated regrowth in adults with severe alopecia areata.1

DHT is part of the biology of pattern hair loss. A blood level alone does not describe how a person's follicles respond. The hair pattern, examination, medical history and reproductive plans help establish whether hormone-directed treatment fits.

Devices, procedures, nutritional support and changes in hair care have their own purposes. Treatment is the broad term covering these options.

Compare routes and practical demands

Oral and topical formulations differ in exposure, adverse effects and daily effort. In a 24-week trial in men with pattern hair loss, oral minoxidil did not demonstrate overall superiority to topical minoxidil. Route therefore deserves a specific reason.2

Scalp tolerance, other medications and the routine a person can sustain are part of that decision. Guidance on low-dose oral minoxidil includes medical assessment, precautions and monitoring.3

Laser evidence also needs attention to the device and schedule studied. A randomized trial supports the tested equipment and use; a similar-looking device needs its own evidence.4

A treatment earns its place through the problem it addresses and the benefit it adds.

Understand approval and off-label use

Off-label prescribing uses an approved drug outside its official indication, dose or route. Evidence for the proposed use, alternatives and personal medical circumstances inform the prescribing decision.5

My recommendations set out the treatment direction, expected benefit, precautions and monitoring. The patient's prescriber makes and manages prescription decisions with the patient. This gives local care a specific plan to assess and implement.

Choose a useful sequence

Active scalp disease may need immediate attention. In other situations, preserving hair or improving coverage is the main goal. Starting several treatments together can be justified; introducing them in stages can help identify benefit or a reaction.

Treatments in development also belong in planning. A trial recommendation should identify the verified study, relevant eligibility and practical demands. Investigational treatment is still being evaluated.6

Bring details of previous treatments, their duration and why they stopped. The next recommendation should use that experience to choose a manageable plan and define what would justify continuing or changing it.

References

  1. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022;386:1687-1699. doi:10.1056/NEJMoa2110343. Return to text ↑
  2. Penha MA, Miot HA, Kasprzak M, et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160:600-605. doi:10.1001/jamadermatol.2024.0284. Return to text ↑
  3. Akiska YM, Mirmirani P, Roseborough I, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. 2025;161:87-95. doi:10.1001/jamadermatol.2024.4593. Return to text ↑
  4. Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014;15:115-127. doi:10.1007/s40257-013-0060-6. Return to text ↑
  5. US Food and Drug Administration. Understanding Unapproved Use of Approved Drugs Off Label. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label Return to text ↑
  6. US Food and Drug Administration. Understanding Investigational Drugs. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-investigational-drugs Return to text ↑

Medical disclaimer: FHI Insights is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult a licensed healthcare professional regarding individual health concerns or treatment decisions.